Lipid Profiles of Acute Coronary Syndrome Patients Hospitalized in ICCU of Cipto Mangunkusumo Hospital

Size: px
Start display at page:

Download "Lipid Profiles of Acute Coronary Syndrome Patients Hospitalized in ICCU of Cipto Mangunkusumo Hospital"

Transcription

1 ORIGINAL ARTICLE Lipid Profiles of Acute Coronary Syndrome Patients Hospitalized in ICCU of Cipto Mangunkusumo Hospital Daulat Manurung ABSTRACT Aim: to see which component of the triad lipid that has more important role and frequently found in patients with acute coronary syndrome, focusing on HDL cholesterol. Methods: a lipid profile study has been conducted in 391 patients with acute coronary syndrome (ACS), who have been hospitalized in ICCU of Cipto Mangunkusumo Hospital since January 1 st, 2001 December 31 st, Results: there were 294 male patients (75.2%) and 97 female patients (24.8%), from years age group, with mean value ± The mean value of total cholesterol level was mg/dl ± The LDL cholesterol level was mg/dl ± The mean HDL cholesterol level was mg/dl ± 10.28, mean triglycerides level was mg/dl ± There were 82 patients (21%) with high total cholesterol (> 240 mg/dl), 102 patients (26.1%) with high and very high LDL cholesterol level (> 160 mg/dl), 152 (38.6%) patients with low HDL cholesterol level (< 40 mg/dl), consisted of 126 male patients or 42.9% of total male patients, 26 female patients or 26.8% of total female patients. The number of patients with high / very high triglycerides level (> 200 mg/dl or 500 mg/dl) was 84 patients (21.5%). The number of patients with optimal lipid level, total cholesterol level < 200 mg/dl was 191 patients (48.8%); 82 patients (21%) had LDL cholesterol level < 100 mg/dl, 23 patients (5.9%) had HDL cholesterol level > 60 mg/dl, 226 patients (57.8%) had triglycerides level < 150 mg/dl. There were 260 patients with atherogenic lipid profile (64%), 135 patients with borderline lipid profile (34.5%), and optimal lipid profile was found only in 6 patients (1,5%). The mean value of HDL cholesterol level in male patients was mg/dl ± 9.9, while HDL cholesterol level in female patients was mg/dl ± Principally, lipid profiles of all age groups were evenly distributed. ACS patients with history of family heart disease had a more atherogenic lipid profile compared to lipid profile of patients with hypertension, diabetes mellitus, and cigarette smoking. Division of Cardiology, Department of Internal Medicine Faculty of Medicine, University of Indonesia-dr. Cipto Mangunkusumo Hospital, Jakarta Conclusion: atherogenic lipid profile is more common risk factor in ACS patients than in other non-lipid risk factors. This study also demonstrated that the atherogenic lipid is most commonly found in patient with low HDL cholesterol level and it is least frequently found in patient with optimal lipid profile. Key words : lipid profile, acute coronary syndrome. INTRODUCTION Elevated blood cholesterol level is a main risk factor of atherosclerosis process, which underlies the development of coronary heart disease, including acute coronary syndrome. Total blood cholesterol consists of Low Density Lipoprotein (LDL) cholesterol, which is the largest component of total cholesterol, i.e % of total cholesterol. 1 LDL cholesterol is very atherogenic (a very atherogenic lipoprotein) and it should be decreased and represents the major cause of CHD, it should be decreased. The correlation between elevated LDL cholesterol level and CHD development should be observed as a multi step process, which starts from the young age. 2,3,4 Plaque rupture or erosion usually leads to acute coronary syndrome (acute myocardial infarct, unstable angina pectoris and sudden death caused by coronary heart disease). 5-8 The second cholesterol component is high density lipoprotein (HDL) cholesterol. Normally, it is 20-30% of total cholesterol. HDL cholesterol is one of important lipoproteins and is very potential to prevent atherosclerosis by changing the biology of arterial wall lesion, without being affected by LDL cholesterol level. 9 HDL cholesterol has two mechanisms causing changes in biology of arterial wall lesion. Correlation between blood triglyceride level and CHD may be derived from various mechanisms such as, triglycerides may which cause a more atherogenic LDL cholesterol. It may cause higher clearance rate of HDL cholesterol, which finally causes low HDL cholesterol level. may cause endothelial dysfunction, 196

2 Vol 38 4 October - December 2006 Lipid Profiles of Acute Coronary Syndrome Patients Hospitalized and may stimulate macrophages migration into endothelium. It may also stimulate vascular endothelial to promote thrombogenic mediator synthesis, for example: Plasminogen Activator Inhibitor (PAI-1). 10 NCEP /ATP III regards < 150mg/dL as optimal level mg/dl as borderline level, mg/dl as high level, and > 500 mg/dl as very high level. 1 In this study, we will see, which component of the triad lipid that has more important role and frequently found in patients with acute coronary syndrome, focusing on HDL cholesterol. METHODS This study was a retrospective cross-sectional study based on medical records of ACS patients in Cipto Mangunkusumo Hospital ICCU from January 1 st, 2001 to December 31 st, RESULTS During the course of study (January 1 st, 2001) December 31 st, 2005), there were 568 patients with acute coronary syndrome (ACS) hospitalized in ICCU (Intensive Coronary Care Unit) of Cipto Mangunkusumo Hospital. There were 391 patients, i.e. 294 male (75.2%) and 97 female (24.8%), who had complete lipid profile records including total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. The study also recorded the non-lipid coronary risk factors such as diabetes mellitus in 132 patients (33.8%), hypertension in 229 patients (58.6%), smoking in 205 patients (52.4%), familial heart disease in 61 patients (15.6 %). The subjects age was about years old with mean value of 57.35± The mean value of total cholesterol level was ± 54.84, LDL cholesterol level was ±47.29 mg/dl, HDL cholesterol level was ± mg/dl, and triglycerides level was ± mg/dl. (Table 1) Table 1. Mean Value of Lipid Profile in ACS Lipid Profile Total cholesterol mg/dl ± LDL cholesterol mg/dl ± HDL cholesterol mg/dl ± mg/dl ± There were 82 patients (21%) with high total cholesterol level (> 240 mg/dl), 191 patients (48.8%) with total cholesterol less than 200 mg/dl and 118 patients (30.2%) with borderline cholesterol level between mg/dl. (Table 2) Table 2. Distribution of Total esterol Level in ACS Total esterol of Patient > 240 high borderline < 200 desired There were 41 patients (10.5%) with LDL cholesterol level more than 190 mg/dl (very high level), 61 patients (15.6%) with LDL cholesterol level between mg/dl (high level), 101 patients (25.8%) with LDL cholesterol level between mg/dl, 106 patients (27.1%) with LDL cholesterol level between mg/dl, and 82 patients (21%) with LDL cholesterol level less than 100 mg/dl (optimal level). (Table 3) Table 3. Distribution of LDL esterol Level in ACS LDL esterol of Patient > 190 very high high nearly high beyond optimal < 100 optimal Patients with high HDL cholesterol level > 60 mg/dl were 23 patients (5.9%) of all ACS patients, consisting of 12 male patients (3.1%) and 11 female patients (11.3%). (Table 4) Table 4. Distribution of Level in ACS of Patient > 60 mg/dl high mg/dl borderline < 40 mg/ dl low There were 126 male patients (42.9 %) and 26 female patients (26.8%) among total number of 152 patients (38.6%) with low HDL cholesterol level, less than 40 mg/dl. (Table 5) While total HDL cholesterol level in male was mg/dl ± 9.9, and the level in female was mg/dl ±

3 Daulat Manurung Acta Med Indones-Indones J Intern Med Table 5. Distribution of Level < 40 mg/dl in ACS Sex of Patient Male (294 subjects) Female (97 subjects) Total (391 subjects) There were 84 patients (21.5%) with high triglyceride level > 200 mg/dl, 2 patients with very high triglyceride level > 500 mg/dl (0.5%). There were also 226 patients with triglyceride level of <150 mg/dl (57.8 %) and 81 patients with triglyceride level of mg/dl (20.7%). (Table 6) Table 6. Distribution of Triglyceride Level in ACS < > 500 of Patient Furthermore, there were 82 patients (21%) with high total cholesterol level more than 240 mg/dl, 102 patients (26.1%) with high LDL cholesterol level more than 160mg/dl. There were 152 patients (38.6%) with low HDL cholesterol level < 40 mg/dl and 84 patients (21.5%) with high triglyceride level > 200 mg/dl. (Table 7) Table 7. Distribution of Patients with Atherogenic Lipid in ACS Lipid Category Total esterol > 240 LDL esterol > 160 Low < 40 > In keeping with optimal lipid profile level, there were 191 patients (48.8%) with total cholesterol level < 200 mg/dl, 82 patients (21%) with LDL cholesterol level < 100 mg/dl. There were also 23 patients (5.9%) with high HDL cholesterol > 60 mg/dl and 226 patients (57.8%) with triglyceride level < 150 mg/dl. (Table 8). But according to the combination of atherogenic lipid triad (High LDL level, low HDL level, and high triglyceride level), there were 10 patients (2.6%) who had complete atherogenic lipid profile. Table 8. Distribution of Patients with Optimal Lipid Level in ACS Lipid Category Total esterol <200 LDL esterol < 100 > 60 < If it calculated based on two combination of atherogenic lipid, there were 68 patients (17.4 %), while if it calculated based on single atherogenic lipid, there were 172 patients (44%). No lipid atherogenic was found in 141 patients (36 %). Moreover, if the three lipid types were optimal, only six patients were found (1.5 %). There were 141 patients 6 patients 135 patients with borderline lipid profile (34.5 %). (Table 9) Table 9. Combination of Lipid Triad in ACS patients Lipid Combination N % 3 atherogenic lipid atherogenic lipid atherogenic lipid Borderline lipid Optimal lipid In keeping with percentage of two atherogenic lipid combination, there were 32 patients with combination of low HDL level and high triglyceride level (8.2 %). There were 21 patients with combination of high triglyceride level and high LDL level (5.4 %) and 15 patients with combination of low HDL level and high LDL level (3.8%). (Table 10) Table 10. Combination of Two Atherogenic Lipid in 391 ACS Patients Lipid Combination N % Low High High LDL esterol, High High LDL esterol, Low HDL esterol Total Lipid distribution based on Age Group may be seen on table 11. While lipid profile in patients with non-lipid risk factor of coronary heart disease, hypertension, smoking, diabetes mellitus and history of familial heart disease may be seen in table 12, 13, 14,

4 Vol 38 4 October - December 2006 Lipid Profiles of Acute Coronary Syndrome Patients Hospitalized Table 11. Distribution of Lipid Profile Based on Age Group Age. Group Num % Total LDL HDL Trig ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ± ±62.70 >= ± ± ± ±60.13 Table 12. Lipid Profile in ACS Patients with Hypertension (N = 229; 58.8%) Total esterol LDL esterol ± ± ± ± Table 13. Lipid Profile in ACS Patients with Smoking Habit (N = 205; 52.4%) Total esterol LDL esterol HDL esterol ± ± ± ± Table 14. Lipid Profile in ACS Patients with Diabetes (N = 132; 33.7%) Total esterol LDL esterol ± ± ± ± Table 15. Lipid Profile in ACS Patients With History of Familial Heart Disease Total esterol LDL esterol ± ± ± ± DISCUSSION The lipid profile including total cholesterol level, LDL cholesterol level, HDL cholesterol level, and triglyceride level obtained from other studies in western countries/ from literature have similar results to this study. 11,12 A study of CHD population in Jakarta also has similar result. 13 (Table 16) There is a correlation between low HDL cholesterol level and other atherogenic factors. Most of individuals with low HDL cholesterol level demonstrate a correlation to high triglycerides and remnant lipoprotein levels (quoted of reference 1). In addition, low HDL cholesterol level usually correlated to small dense LDL particle. 27 There is strong correlation between low HDL cholesterol level, high LDL cholesterol level, and high triglycerides level, which demonstrate the term of Lipid Triad as mentioned before. In this study, we may observe that among atherogenic lipid, combinations, the combination of low HDL cholesterol level and low triglycerides is the most 199

5 Daulat Manurung Acta Med Indones-Indones J Intern Med Table 16. Comparison of Lipid Profile in Present Study and Other Studies (Nissen et al 11 ) (Nissen et al 12 ) (Sarwono 13 ) (Present Study) Total esterol 204 (41.2) 232 ± ± ± LDL esterol (34.3) 150 ± ± ± (11.1) 426 ± ± ± (81.7) ± ± ± common, including 32 patients (8.2%). While the combination of high LDL cholesterol level and high triglycerides level is on the second rank with 21 patients (5.4%) and the least frequent combination is high LDL cholesterol disorder and short of breath, which is found in 15 patients or 3.8%. (Table 10) It is also noted that among 391 ACS patients, there are 250 patients (64%) who have atherogenic lipid, and the most common is only in single atherogenic lipid found in 172 patients (44%). About 68 patients (17.4%) have combination of two atherogenic lipid, while optimal lipid profile is only found in 6 patients (1.5%) of 391 patients. In addition, lipid profile of borderline level is found in 135 patients (34.5%). (Table 9) Among four non-lipid coronary risk factors, lipid profile of ACS patients with familial history have a more atherogenic lipid profile, which indicates higher LDL cholesterol and triglycerides level compared to other patients with smoking habit, hypertension and diabetes mellitus. The most common non-lipid coronary risk factors are hypertension in 229 patients (58.8%), followed by smoking in 205 patients (52.4%), diabetes in 132 patients (33.7%), and the least common is history of familial heart disease in 61 patients (15.1%). In keeping with the distribution of atherogenic lipid profile, low HDL cholesterol level is the most common atherogenic lipid, which is found in 152 patients (38.6%), while high LDL cholesterol level, high triglycerides level and high total cholesterol level are relatively similar, which are 26.1%, 21.5% and 21 % respectively (Table 7). Furthermore, among 152 patients with low HDL cholesterol, there are 126 male patients (42.9%) and 26 female patients (26.8%). This result is lower than in Framingham study, which shows 57% male CHD patients with HDL cholesterol level < 40 mg/dl, while the CARE study indicates 40% female patients with acute infarct have HDL cholesterol level of < 40mg/dL. But from these data, it is clear that ACS patients with low HDL level are more found in male group (42.9%) than the female (26.8%). In contrast, high HDL cholesterol level is more frequently found in female group (11.3%) than male (3.1%) (table 4.5). The mean value of HDL cholesterol level is lower in male group (41.75mg/dl ±9.9) compared to female (46.16mg/dL ± 10.74). These data 13, are similar to data found from previous studies. In relation to optimal lipid profile, the most common is optimal triglycerides level < 150 mg/dl, which is found in 226 patients (57.8%), followed by total cholesterol level < 200 in 191 patients (48.8%) and the least frequent is HDL cholesterol, which is only found in 23 patients (5.9%). (Table 8) The most common lipid distribution is total cholesterol level of < 200 in 191 patients (48.8%). LDL cholesterol level between is found in 207 patients (52.9%), borderline HDL cholesterol level of mg/dl is found in 216 patients (55.5%), triglycerides level of < 150 is found in 226 patients (57.8%). (Table 2, 3, 4, 6) While the composition of lipid profile based on age group is evenly distributed, although the age group of years has higher triglycerides level compared to other age groups, and the age group > 80 years has higher total cholesterol and LDL level. Higher cholesterol level is found in the age group of > 70 years and > 80 years compared to other age groups. It is interesting that the younger age group has a lower HDL cholesterol level, lower total cholesterol level, lower LDL cholesterol level, and also lower triglycerides level (isolated low HDL cholesterol?) (quoted of reference 1), but it only occurs in 2 patients, therefore it is difficult to regard this as a comparison. (Table 11) CONCLUSION The composition of lipid profile in this study is relatively similar to other data in western countries. Among 391 ACS patients, it is found that the most common atherogenic lipid is low HDL cholesterol about 38.6%, while the number/percentage of other atherogenic lipid is relatively similar. There are 64% atherogenic lipid found as single atherogenic lipid, and there are only about 1.5% who have optimal lipid profile, and 34.5% who have borderline lipid profile. It also demonstrates that mean value of HDL cholesterol level is higher in female than in male group. Combination of low HDL cholesterol and 200

6 Vol 38 4 October - December 2006 Lipid Profiles of Acute Coronary Syndrome Patients Hospitalized high triglycerides level is about 8.2%, high LDL cholesterol and high triglycerides level are about 5.4% and combination of high LDL cholesterol level and low HDL cholesterol level is about 3.8%. The most common optimal lipid profile is triglycerides and total cholesterol level, i.e. 57.8% and 48.8% respectively. The most common non-lipid coronary risk factor is hypertension (58.8%) and smoking (52.4%). The more atherogenic lipid profile lipid is found in patients with history of familial heart disease. This study is a retrospective study, therefore it is not known whether the patient already had any previous therapy of hypolipidemic agents, and there is no record about it. This obviously affects the cholesterol examination of hospitalized ACS patients. Other risk factors, such as metabolic syndrome, are not recorded, but the major coronary risk factors have been included in this study. Since low HDL cholesterol is the largest component of other atherogenic lipids, education about increasing HDL cholesterol is important in order to provide primary prevention by emphasizing the importance of total health life changes ACKNOWLEDGEMENT I would like to thank dr. Taufik for his endeavor to collect the medical data in this study and to Ms. Sri Rahayu Kadarwati, SKM for her help in preparing this manuscript. REFERENCES 1. Third Report of the National Kolesterol Education Program (NCEP), Expert Panel On Detection, Evaluation, and Treatment of High Blood Kolesterol in Adults (Adult Treatment Panel III/ ATP III). (Final Report). National Institutes of Health. National Heart, Lung, And Blood Institute. NIH Publication No September Stary HC, Blankenhorn DH, et al. A definition of the intima of human arteries and of its atheroslerosis prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1992;85: Stary HC, ChandLer AB, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler Thromb. 1994:14: Stary HC, ChandLer AB, et al. A definition of advanced types of atherosclerotic lesions and histological classification of atherosclerosis; a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92: Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91: Libby P, Schoenbeck U, et al. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998;104(2A):14S-8S. 7. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet. 1999;353(suppl II):S115-S9. 8. Theroux P, Fuster V. Acute coronary syndromes: unstable angina and non-q-wave myocardial infarction. Circulation. 1998;97: Castelli W. esterol and lipids in the risk of coronary artery disease. The Framingham Heart Study. Can J Cardiol. 1988;4(suppl A):5a-10a. 10. Hokanson J, Austin M. Plasma triglyceride and coronary risk.a metaanalysis. Circulation. 1993, 88: Nissen Steven E, Nicholls SJ, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial. JAMA. 2006;295: Nissen Steven E, Tuzcu E Murat, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1): Waspadji S. Lipid profile in urban population. Jakarta: a decade interval. Jakarta diabetes meeting Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; Austin MA, Rodriguez BL, et al. Low-density lipoprotein particle size, triglycerides, and high density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol. 2000;86: Johnson CL, Rifkind BM, et al. Declining serum total cholesterol levels among US adults: the national health and nutrition examination surveys. JAMA. 1993;269: Kannel WB. Range of serum cholesterol in the population developing coronary artery disease. Am J Cardiol. 1995; 76(suppl):69C-77C. 17. Lewis SJ, Sacks FM, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events trial. J Am Coll Cardiol. 1998;32:

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.

More information

Education. Panel. Triglycerides & HDL-C

Education. Panel. Triglycerides & HDL-C Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified

More information

High Blood Cholesterol

High Blood Cholesterol National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour

More information

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS

More information

Cardiovascular Disease and the Endothelium

Cardiovascular Disease and the Endothelium Cardiovascular Disease and the Endothelium by Jeffrey Porro A series of articles for general audiences This series of essays was developed as part of FASEB s efforts to educate the general public, and

More information

African Americans & Cardiovascular Diseases

African Americans & Cardiovascular Diseases Statistical Fact Sheet 2013 Update African Americans & Cardiovascular Diseases Cardiovascular Disease (CVD) (ICD/10 codes I00-I99, Q20-Q28) (ICD/9 codes 390-459, 745-747) Among non-hispanic blacks age

More information

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES

LIPID PANEL CHOLESTEROL LIPOPROTEIN, ELECTROPHORETIC SEPARATION LIPOPROTEIN, DIRECT MEASUREMENT (HDL) LDL DIRECT TRIGLYCERIDES Test Code Test Name CPT CHOL Cholesterol, Serum 82465 HDL HDL, (High Density Lipoprotein) 83718 TRIG Triglycerides, Serum 84478 FTRIG Triglycerides (Fluid) 84478 LIPID Lipid Panel 80061 LDL LDL (Low Density

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:

More information

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process

More information

Cardiovascular Disease Risk Factors

Cardiovascular Disease Risk Factors Cardiovascular Disease Risk Factors Risk factors are traits and life-style habits that increase a person's chances of having coronary artery and vascular disease. Some risk factors cannot be changed or

More information

ACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc

ACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc ACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc ABSTRACT Objective; In this study we looked at the demographic characteristics and the frequency of the various risk

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).

Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Complete Summary GUIDELINE TITLE (1)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment

More information

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME 1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome

More information

Will The Coronary Calcium Score Affect the Decision To Treat With Statins?

Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Amresh Raina M.D. Division of Cardiology University of Pennsylvania Disclosures No financial relationships relevant to this presentation

More information

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures.

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures. JSNA Coronary heart disease 1) Key points 2) Introduction 3) National picture 4) Local picture of CHD prevalence 5) Mortality from coronary heart disease in Suffolk County 6) Trends in mortality rates

More information

Statins for Hyperlipidemia (High Cholesterol)

Statins for Hyperlipidemia (High Cholesterol) Statins for Hyperlipidemia (High Cholesterol) Examples of statin drugs Brand Name Mevacor Pravachol Zocor Lescol, Lescol XL Lipitor Crestor Chemical Name lovastatin pravastatin sodium simvastatin fluvastatin

More information

LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts.

LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts. LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts Introduction While both small and large LDL particles may be atherogenic,

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing

Primary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading

More information

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines

Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Amit Sachdeva, MD, a Christopher P. Cannon, MD, b Prakash C. Deedwania,

More information

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study European Journal of Clinical Investigation (2007) 37, 925 932 DOI: 10.1111/j.1365-2362.2007.01888.x Blackwell Publishing Ltd Review Assessing risk of myocardial infarction and stroke: new data from the

More information

How To Treat Dyslipidemia

How To Treat Dyslipidemia An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates

More information

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,

More information

NCD for Lipids Testing

NCD for Lipids Testing Applicable CPT Code(s): NCD for Lipids Testing 80061 Lipid panel 82465 Cholesterol, serum or whole blood, total 83700 Lipoprotein, blood; electrophoretic separation and quantitation 83701 Lipoprotein blood;

More information

MY TYPE 2 DIABETES NUMBERS

MY TYPE 2 DIABETES NUMBERS BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,

More information

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering

More information

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized

More information

Coronary Heart Disease (CHD) Brief

Coronary Heart Disease (CHD) Brief Coronary Heart Disease (CHD) Brief What is Coronary Heart Disease? Coronary Heart Disease (CHD), also called coronary artery disease 1, is the most common heart condition in the United States. It occurs

More information

The incidence of coronary heart disease (CHD) peaks in the elderly population. In secondary

The incidence of coronary heart disease (CHD) peaks in the elderly population. In secondary SPECIAL ARTICLE Cholesterol Lowering in the Elderly Population Scott M. Grundy, MD, PhD; James I. Cleeman, MD; Basil M. Rifkind, MD; Lewis H. Kuller, MD, DrPH; for the Coordinating Committee of the National

More information

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

THE THIRD REPORT OF THE EXpert

THE THIRD REPORT OF THE EXpert SPECIAL COMMUNICATION Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults

More information

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?

At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? European Heart Journal (2001) 22, 919 925 doi:10.1053/euhj.2000.2484, available online at http://www.idealibrary.com on At what coronary risk level is it cost-effective to initiate cholesterol lowering

More information

The Canadian Association of Cardiac

The Canadian Association of Cardiac Reinventing Cardiac Rehabilitation Outside of acute care institutions, cardiovascular disease is a chronic, inflammatory process; the reduction or elimination of recurrent acute coronary syndromes is a

More information

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One

More information

Dark chocolate as a functional food

Dark chocolate as a functional food Dark chocolate as a functional food Roger Corder William Harvey Research Institute Barts & the London Queen Mary s School of Medicine & Dentistry (r.corder@qmul.ac.uk) William Harvey Research Institute

More information

Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease

Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease

More information

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date

More information

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment

Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).

More information

HEDIS CY2012 New Measures

HEDIS CY2012 New Measures HEDIS CY2012 New Measures TECHNICAL CONSIDERATIONS FOR NEW MEASURES The NCQA Committee on Performance Measurement (CPM) approved five new measures for HEDIS 2013 (CY2012). These measures provide feasible

More information

Guidelines for the management of hypertension in patients with diabetes mellitus

Guidelines for the management of hypertension in patients with diabetes mellitus Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes

More information

YOUR GUIDE TO. Managing and Understanding Your Cholesterol Levels

YOUR GUIDE TO. Managing and Understanding Your Cholesterol Levels YOUR GUIDE TO Managing and Understanding Your Cholesterol Levels Our goal at the Mercy Health Heart Institute is to help you be well. Our experienced team includes cardiologists, cardiovascular surgeons,

More information

EUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events

EUROASPIRE II. European Action on Secondary and Primary Prevention through Intervention to Reduce Events II European Action on Secondary and Primary Prevention through Intervention to Reduce Events Euro Heart Survey Programme European Society of Cardiology-ESC 1 2 Priorities of Coronary Heart Disease Prevention

More information

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015 PROJECT TITLE: Analysis of ECG Exercise Stress Testing and Framingham Risk Score in Chest Pain Patients PRIMARY SUPERVISOR NAME: Dr. Edward Tan DEPARTMENT:

More information

Coronary heart disease (CHD) has an enormous

Coronary heart disease (CHD) has an enormous GLOBAL RISK ASSESSMENT IN CARDIOVASCULAR DISEASE * Steven P. Schulman, MD ABSTRACT Cardiovascular disease is the leading cause of mortality in the United States. Importantly, atherosclerosis begins at

More information

Anti-Atheroscrerotic Drugs

Anti-Atheroscrerotic Drugs Anti-Atheroscrerotic Drugs Masuko Ushio-Fukai, PhD, FAHA Dept. of Pharmacology University of Illinois at Chicago Anti-Atherogenic Drugs: Treatment of Hyperlipidemias Knowledge Objectives: 1) Know the mechanism

More information

GENERAL HEART DISEASE KNOW THE FACTS

GENERAL HEART DISEASE KNOW THE FACTS GENERAL HEART DISEASE KNOW THE FACTS WHAT IS Heart disease is a broad term meaning any disease affecting the heart. It is commonly used to refer to coronary heart disease (CHD), a more specific term to

More information

The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?

The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division

More information

A Practical Approach to Risk Assessment to Prevent Coronary Artery Disease and Its Complications

A Practical Approach to Risk Assessment to Prevent Coronary Artery Disease and Its Complications A Practical Approach to Risk Assessment to Prevent Coronary Artery Disease and Its Complications MacRae F. Linton, MD, and Sergio Fazio, MD, PhD The recent focus on emerging cardiovascular risk factors,

More information

Cardiovascular disease is the leading cause of morbidity

Cardiovascular disease is the leading cause of morbidity electronic health records Implementation of an Electronic Health Record with an Embedded Quality Improvement Program to Improve the Longitudinal Care of Outpatients with Coronary Artery Disease Allan G.

More information

OVERVIEW OF THE ADULT TREATMENT PANEL (ATP) III GUIDELINES *

OVERVIEW OF THE ADULT TREATMENT PANEL (ATP) III GUIDELINES * OVERVIEW OF THE ADULT TREATMENT PANEL (ATP) III GUIDELINES * Roger S. Blumenthal, MD INTRODUCTION Although medical evidence suggests that the mortality rates for cardiovascular disease can be significantly

More information

EPA/DHA Omega-3 Fatty Acids in the Primary and Secondary Prevention of Cardiovascular Disease and the Modification of Risk Factors

EPA/DHA Omega-3 Fatty Acids in the Primary and Secondary Prevention of Cardiovascular Disease and the Modification of Risk Factors EPA/DHA Omega-3 Fatty Acids in the Primary and Secondary Prevention of Cardiovascular Disease and the Modification of Risk Factors Author: Bruce Holub, Ph.D. University Professor Emeritus (University of

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline

Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline Learn and Live SM ACCF/AHA Pocket Guideline Based on the 2010 ACCF/AHA Guideline Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults November 2010 Guideline for Assessment of Cardiovascular

More information

Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003 2012

Prescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003 2012 NCHS Data Brief No. 77 December 4 Prescription Cholesterol-lowering Medication Use in Adults Aged 4 and Over: United States, 3 2 Qiuping Gu, M.D., Ph.D.; Ryne Paulose-Ram, Ph.D., M.A.; Vicki L. Burt, Sc.M.,

More information

Serum testosterone and short-term mortality in men with acute myocardial infarction

Serum testosterone and short-term mortality in men with acute myocardial infarction ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. 3, pp. 249 253 Copyright 2010 Via Medica ISSN 1897 5593 Serum testosterone and short-term mortality in men with acute myocardial infarction Constantin

More information

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38 Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac

More information

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology Objectives Acute Coronary Syndromes Epidemiology and Health Care Impact Pathophysiology Unstable Angina NSTEMI STEMI Clinical Clues Pre-hospital Spokane County EMS Epidemiology About 600,000 people die

More information

Atherosclerosis of the aorta. Artur Evangelista

Atherosclerosis of the aorta. Artur Evangelista Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis

More information

Risk Factors for Fire Fighter Cardiovascular Disease

Risk Factors for Fire Fighter Cardiovascular Disease Risk Factors for Fire Fighter Cardiovascular Disease EXECUTIVE SUMMARY Prepared by: Jefferey L. Burgess, MD, MS, MPH Mel and Enid Zuckerman College of Public Health The University of Arizona The Fire Protection

More information

Health-care expenditure on cardiovascular diseases 2008 09

Health-care expenditure on cardiovascular diseases 2008 09 Health-care expenditure on cardiovascular diseases 2008 09 Health-care expenditure on cardiovascular diseases 2008 09 Australian Institute of Health and Welfare Canberra Cat. no. CVD 65 The Australian

More information

Improving cardiometabolic health in Major Mental Illness

Improving cardiometabolic health in Major Mental Illness Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic

More information

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität

More information

Can Common Blood Pressure Medications Cause Diabetes?

Can Common Blood Pressure Medications Cause Diabetes? Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately

More information

Up to half of all events associated with cardiovascular REVIEW ARTICLE. C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease

Up to half of all events associated with cardiovascular REVIEW ARTICLE. C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease Michael B. Clearfield, DO Recent research has focused on the use of high-sensitivity C-reactive protein (hs-crp), a marker of inflammation,

More information

Potential Clinical and Economic Impact of Statin Formulary Management

Potential Clinical and Economic Impact of Statin Formulary Management Potential Clinical and Economic Impact of Statin Formulary Management Karol E. Watson, MD Summary The evidence is clear that aggressive management of cardiac risk factors is beneficial and generally safe

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Making Sense of the New Statin guidelines. They are more than just lowering your cholesterol!

Making Sense of the New Statin guidelines. They are more than just lowering your cholesterol! Making Sense of the New Statin guidelines They are more than just lowering your cholesterol! No Disclosures Margaret (Peg) O Donnell DNPs, FNP, ANP B-C, FAANP Senior Nurse Practitioner South Nassau Communities

More information

The Intensive Statin Therapy Myth

The Intensive Statin Therapy Myth F o c u s Michael Shechter MD MA, Roy Beigel MD, Shlomi Matetzky MD, Dov Freimark MD and Pierre Chouraqui MD Heart Institute, Sheba Medical Center, Tel Hashomer, Israel Affiliated to Sackler Faculty of

More information

Cholesterol and Triglycerides What You Should Know

Cholesterol and Triglycerides What You Should Know Cholesterol and Triglycerides What You Should Know Michael T. McDermott MD Professor of Medicine Endocrinology Practice Director Division of Endocrinology, Metabolism and Diabetes University of Colorado

More information

Sinclair Community College, Division of Allied Health Technologies

Sinclair Community College, Division of Allied Health Technologies Sinclair Community College, Division of Allied Health Technologies Health Promotion for Community Health Workers Cardiovascular disease, stroke, and cancer Class #5 High Blood Cholesterol (date) Course

More information

High Blood Cholesterol What you need to know

High Blood Cholesterol What you need to know National Cholesterol Education Program High Blood Cholesterol What you need to know Why Is Cholesterol Important? Your blood cholesterol level has a lot to do with your chances of getting heart disease.

More information

METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS

METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS METABOLIC SYNDROME IN A CORRECTIONS POPULATION TREATED WITH ANTIPSYCHOTICS Andrew M. Cislo, PhD Megan J. Ehret, PharmD, MS, BCPP Robert L. Trestman, MD, PhD Kirsten Shea, MBA www.uchc.edu Background Metabolic

More information

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014

JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014 JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss

More information

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know Acute Coronary Syndrome What Every Healthcare Professional Needs To Know Background of ACS Acute Coronary Syndrome (ACS) is an umbrella term used to cover a spectrum of clinical conditions that are caused

More information

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate

More information

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell

More information

Diabetes and Heart Disease

Diabetes and Heart Disease Diabetes and Heart Disease Diabetes and Heart Disease According to the American Heart Association, diabetes is one of the six major risk factors of cardiovascular disease. Affecting more than 7% of the

More information

INSULIN RESISTANCE AND COMPENSATORY HYPERINSULINEMIA: THE LINCHPIN BETWEEN OBESITY AND CARDIOVASCULAR DISEASE

INSULIN RESISTANCE AND COMPENSATORY HYPERINSULINEMIA: THE LINCHPIN BETWEEN OBESITY AND CARDIOVASCULAR DISEASE May 2008 (Vol. 1, Issue 2, pages 4-10) INSULIN RESISTANCE AND COMPENSATORY HYPERINSULINEMIA: THE LINCHPIN BETWEEN OBESITY AND CARDIOVASCULAR DISEASE By Gerald M. Reaven, MD, Division of Cardiovascular

More information

PREVENTIVE CARDIOLOGY CURRICULUM. Overview

PREVENTIVE CARDIOLOGY CURRICULUM. Overview PREVENTIVE CARDIOLOGY CURRICULUM Overview The primary goal of the Preventive Cardiology curriculum for the University of Wisconsin Cardiovascular Medicine Fellowship is to provide the knowledge and skills

More information

Primary Care Physicians' Agreement With NCEP-ATP II Guidelines in Hylipidemia Management

Primary Care Physicians' Agreement With NCEP-ATP II Guidelines in Hylipidemia Management Primary care physicians' agreement with NCEP-ATP II Guidelines in management of hyperlipidemia Author(s): Khalid S. Al- Gelban Vol. 16, No. 1 (2005-01 - 2005-03) Biomedical Research 2005; 16 (1): 73-83

More information

How Do I Know The Pauling Therapy Is Working? And, How Long Will It Take?

How Do I Know The Pauling Therapy Is Working? And, How Long Will It Take? How Do I Know The Pauling Therapy Is Working? And, How Long Will It Take? These are the 2 questions my customers ask most often. These are also the 2 questions that are the hardest to answer. So, I have

More information

ECG may be indicated for patients with cardiovascular risk factors

ECG may be indicated for patients with cardiovascular risk factors eappendix A. Summary for Preoperative ECG American College of Cardiology/ American Heart Association, 2007 A1 2002 A2 European Society of Cardiology and European Society of Anaesthesiology, 2009 A3 Improvement,

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience

Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience International Scholarly Research Network ISRN Cardiology Volume 2012, Article ID 874706, 5 pages doi:10.5402/2012/874706 Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular

More information

Listen to your heart: Good Cardiovascular Health for Life

Listen to your heart: Good Cardiovascular Health for Life Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular

More information

Darlene Langhoff St. Thomas More High Ron Gerrits MSOE

Darlene Langhoff St. Thomas More High Ron Gerrits MSOE Darlene Langhoff St. Thomas More High Ron Gerrits MSOE Investigating the Scene DNA analysis The Findings Crime scene is set up (optional power point ) Tip: Set up crime scene and have students take photos

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR

More information

Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men

Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men G. Engström, MD, PhD; P. Lind, MD; B. Hedblad, MD, PhD; L. Stavenow, MD, PhD; L.

More information

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.

BMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease. March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding

More information

Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works?

Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works? Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works? DAVID P. GOWMAN, D.O. S E C T I O N CHIEF, CARDIOLOGY P R O G R A M D I R E C T O R, CARDIOLOGY F E L L O W S H I P B

More information

Cardiovascular Effects of Drugs to Treat Diabetes

Cardiovascular Effects of Drugs to Treat Diabetes Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:

More information

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY

MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY MISSING DATA ANALYSIS AMONG PATIENTS IN THE PINNACLE REGISTRY In order to improve the efficiency of PINNACLE Registry data analytics, a missing data analysis has been conducted on PINNACLE Registry data

More information

THE RISK OF HEART ATTACK IN LONE MOTHERS by Asma Al Bulushi. I had been working as a nurse in the cardiology intensive care unit at Hamad Hospital

THE RISK OF HEART ATTACK IN LONE MOTHERS by Asma Al Bulushi. I had been working as a nurse in the cardiology intensive care unit at Hamad Hospital Al Bulushi, A. (2010). The risk of heart attack in lone mothers. UCQ Nursing Journal of Academic Writing, Winter 2010, 19 27. THE RISK OF HEART ATTACK IN LONE MOTHERS by Asma Al Bulushi I had been working

More information

Rheumatoid Factor is a Strong Risk Factor for Coronary Artery Disease in Men with Metabolic Syndrome

Rheumatoid Factor is a Strong Risk Factor for Coronary Artery Disease in Men with Metabolic Syndrome Original Article RF is a Risk Factor for CAD in MS Men Acta Cardiol Sin 2010;26:89 93 Coronary Heart Disease Rheumatoid Factor is a Strong Risk Factor for Coronary Artery Disease in Men with Metabolic

More information

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland

Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for

More information

CORPORATE WELLNESS PROGRAM

CORPORATE WELLNESS PROGRAM CORPORATE WELLNESS PROGRAM WELLNESS Wellness has become an increasingly relevant issue in companies large and small as organizations have come to realize how proactively addressing health and wellness

More information